Untitled

Abstract

Cancer immunotherapy has significantly increased patients' chances of survival and quality of life as compared to earlier standards of care (such as chemotherapy, radiation, and surgery). From the metastatic stage to the adjuvant and neoadjuvant settings in many cancer types, immunotherapy has now firmly established itself as a novel pillar of cancer care. In this review article, we emphasise how the development of cancer immunotherapy led to findings that are today considered best practises. We also show out the existing drawbacks and restrictions of cancer checkpoint immunotherapy and the ways in which cutting-edge research is attempting to address these issues.